EGFL7 meets miRNA-126: an angiogenesis alliance by Nikolic, Iva et al.
JOURNAL OF
ANGIOGENESIS RESEARCH
Nikolic et al. Journal of Angiogenesis Research 2010, 2:9
http://www.jangiogenesis.com/content/2/1/9
Open Access REVIEW
© 2010 Nikolic et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Review EGFL7 meets miRNA-126: an angiogenesis alliance
Iva Nikolic, Karl-Heinz Plate and Mirko HH Schmidt*
Abstract
Blood vessels form de novo through the tightly regulated programs of vasculogenesis and angiogenesis. Both 
processes are distinct but one of the steps they share is the formation of a central lumen, when groups of cells 
organized as vascular cords undergo complex changes to achieve a tube-like morphology. Recently, a protein termed 
epidermal growth factor-like domain 7 (EGFL7) was described as a novel endothelial cell-derived factor involved in the 
regulation of the spatial arrangement of cells during vascular tube assembly. With its impact on tubulogenesis and 
vessel shape EGFL7 joined the large family of molecules governing blood vessel formation. Only recently, the 
molecular mechanisms underlying EGFL7's effects have been started to be elucidated and shaping of the extracellular 
matrix (ECM) as well as Notch signaling might very well play a role in mediating its biological effects. Further, findings in 
knock-out animal models suggest miR-126, a miRNA located within the egfl7 gene, has a major role in vessel 
development by promoting VEGF signaling, angiogenesis and vascular integrity. This review summarizes our current 
knowledge on EGFL7 and miR-126 and we will discuss the implications of both bioactive molecules for the formation 
of blood vessels.
Introduction
Vasculogenesis and angiogenesis are basic processes
through which new blood vessels arise. Vasculogenesis
entails the differentiation of mesodermal cells into
endothelial precursor cells (angioblasts). This is followed
by the formation of primitive blood vessels which are
subsequently refined and transformed into a functional
vascular network by the process of angiogenesis [1,2].
The execution of these tightly regulated programs
depends on a vast array of factors whose identification
has been a prime focus of cardiovascular research in the
last two decades. One of the newly described molecular
players in the field of blood vessel formation is EGFL7, a
protein also known as VE-statin, MEGF7, Notch4-like
protein or Zneu1. Initial studies on the role of EGFL7 in
the vascular system were compiled by Soncin et al., who
showed that EGFL7 inhibited the migration but not the
proliferation of human aortic smooth muscle cells in vitro
[3]. This indicated that EGFL7 might have a role in vessel
maturation. However, a keynote publication of Parker et
al. in 2004 established the role of egfl7 as an important
tubulogenic factor in the process of vasculogenesis [4].
EGFL7 structure, temporal and spatial distribution
Initially, EGFL7 was described as a 30 kD protein exclu-
sively expressed by vascular endothelial cells [3]. The pro-
tein is conserved among vertebrates but an orthologue is
also found in Drosophila melanogaster (CG7447) (Figure
1). Two alternative splice variants of EGFL7 have been
described in the mouse genome [3]. The transcripts con-
tain the same protein coding region and display 73%
sequence identity to human EGFL7 on the protein level
[5]. The analysis of human egfl7 revealed the existence of
three alternative isoforms that contain the same open
reading frame but are transcribed from separate promot-
ers [6] (Figure 2).
In vertebrates the egfl7 gene encodes the biologically
active miRNAs miR-126 and miR-126*. Both are relevant
for the development of the cardiovascular system and
have been implicated in cardiovascular diseases as well as
the formation of cancer [7-10]. The structural assembly
of the encoded protein is modular with an N-terminal
signal secretion peptide, followed by an Emilin-like
d o m a i n  ( E M I )  t h a t  i s  s u c c e e d e d  b y  t w o  E G F - l i k e
domains. The distal domain belongs to the Ca2+-binding
EGF-like domains [3,4]. Typically these domains are asso-
ciated with multimeric proteins involved in protein-pro-
tein interactions [11] and have been described in secreted
proteins that partially incorporate into the ECM [11,12].
* Correspondence: mirko.schmidt@kgu.de
1 Institute of Neurology (Edinger Institute), Johann Wolfgang Goethe University 
School of Medicine, Heinrich-Hoffmann-Str. 7, Frankfurt am Main, D-60528, 
Germany
Full list of author information is available at the end of the articleNikolic et al. Journal of Angiogenesis Research 2010, 2:9
http://www.jangiogenesis.com/content/2/1/9
Page 2 of 10
Initial expression analyses indicated EGFL7 is
restricted to the vascular endothelium at all stages of
mouse development [5,13]. However, later work by Cam-
pagnolo et al. demonstrated the presence of EGFL7 in the
primordial germ cells during homing into the gonads
[14]. Most importantly, EGFL7 is expressed within the
neurons of adult mice, which suggests EGFL7 serves
diverse biological functions in various tissues and not
only in the vascular system [15]. EGFL7 becomes detect-
able at the blastocyst stage during mouse development
with a marked increase in expression levels at embryonic
day E7.5 to E8.5. Subsequently, expression remains at a
constant level [3,5]. Upon birth, EGFL7 becomes down-
regulated in the vascular system and significant levels of
the protein are only maintained in a subset of vessels in
the lung, heart, kidney, spleen and uterus. High expres-
sion levels of EGFL7 are regained upon the onset of phys-
iological angiogenesis, e.g. in the uterus during
pregnancy [13] or alternatively, under pathological condi-
tions of vessel formation sub s e q u e n t  t o  a r t e r i a l  i n j u r y
[13], hypoxic insult [16] or in human solid tumors [4]. In
sum, the striking temporal and spacial expression pattern
of EGFL7 indicates a function of this protein in blood
vessel formation and remodeling.
EGFL7 in the extracellular matrix
The ECM is one of the key components of the vascular
system as it maintains the organization and regulation of
endothelial cells [17]. The ECM supports endothelial cell
proliferation, migration, survival and morphogenesis
during blood vessel formation. Primarily, this occurs
through adhesive interactions with integrins on the
endothelial cell surface. In addition, ECM proteins may
function to sequester angiogenic cytokines allowing for
the coordination of signals transduced via growth factor
receptors and integrins [18,19]. Several parameters indi-
cate EGFL7 is associated with the ECM. First, when over-
expressed in fibroblasts, EGFL7 is mainly detected in the
ECM fraction and the cell lysates and only little amounts
of the protein are spotted in the conditioned medium.
This suggests EGFL7 remains largely attached to the cell
surface, most likely through interactions with ECM mole-
cules [20]. Furthermore, the deposition of EGFL7 in the
ECM is facilitated by certain types of matrix proteins,
such as fibronectin and collagen type I, whereas laminin
and collagen type IV do not exert such an effect [20].
Last, EGFL7 has been shown to promote endothelial cell
adhesion and focal complex formation although not as
efficiently as classical ECM molecules like collagen or
fibronectin do [4]. In a recent study, Lelievre et al. used a
Figure 1 Domain organization of EGFL7. The modular assembly of EGFL7's domains is conserved among vertebrate species. The protein contains 
an N-terminal signal secretion peptide, an EMI domain, two EGF-like domains (the distal one binds Ca2+) and a C-terminal coiled-coil structure. The 
EGFL7 orthologue CG7447 in Drosophila melanogaster shares the same overall structure but differs in total length.Nikolic et al. Journal of Angiogenesis Research 2010, 2:9
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transgenic mouse model to express EGFL7 in the epider-
mis and detected a colocalization of EGFL7 and elastic
fibers in the ECM of epidermal blood vessels. Such they
identified EGFL7 as a negative regulator of vascular elas-
togenesis [21]. Elastic fibers are the largest structures in
the ECM with a very complex organization. Elastin as one
of the key fiber components is produced in a process that
includes cross-linking of tropoelastin molecules by a fam-
ily of lysyl oxidases (LOXs) [22]. The colocalization of
EGFL7 with the elastic fibers caused an inhibition of the
enzymatic activity of LOXL2 by direct interaction and
interfered with the process of elastin deposition [21].
Enzymes of the LOX family cross-link elastin and colla-
gen [23] therefore one may speculate that EGFL7 partici-
pates in the shaping of the ECM thereby indirectly
affecting endothelial cell functions such as migration.
Particularly, these findings are interesting because EGFL7
molecules harbor conserved domains that are typically
associated with ECM proteins. The EMI domain is a
cysteine-rich repetitive element often detected in extra-
cellular proteins that form multimers, e.g. emilin-1 and
emilin-2. Likewise, EGF-like domains are frequently
found in extracellular proteins like the constituents of
elastic fibers [11,24] or common ECM molecules like
laminin and tenascin [12]. Taken together, data suggest
EGFL7 as a putative novel component of the ECM giving
clues as to how it affects endothelial cells.
EGFL7 in vasculogenesis
Early in embryonic development several inductive cues,
e.g. members of the fibroblast growth factor (FGF) or the
bone morphogenetic protein (BMP) families, initiate the
Figure 2 Localization of miR-126/miR-126* within the primary human EGFL7 transcript. This is a schematic representation of three alternative 
primary human EGFL7 transcripts, which initiate from separate promoters but contain the same open reading frame. Non-coding exons are indicated 
in uncolored boxes, coding exons in colored ones. miR-126 and miR-126* are localized within intron 7 of EGFL7 in all vertebrates.Nikolic et al. Journal of Angiogenesis Research 2010, 2:9
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differentiation of hemangioblasts from the undifferenti-
ated mesoderm [25,26]. Hemangioblasts form aggregates
in which the inner cells develop into hematopoietic pre-
cursors and the outer population eventually gives rise to
endothelial cells. Subsequently, endothelial precursor
cells or angioblasts differentiate and assemble into a
primitive vascular network. Commonly, this process is
referred to as vasculogenesis [27]. Solid evidence for a
role of egfl7 in the vasculature was presented by Parker et
al. in their study concerning the role of egfl7 in vascular
tube formation during vasculogenesis [4]. During the
process of primitive plexus formation cells do not directly
assemble into tubes but first aggregate side by side to
form cord-like structures which in later stages acquire a
vascular lumen through the process of tubulogenesis [28].
Gradually, angioblasts start to separate during cord-to-
tube transition due to the relocalization and modification
of cell junctions, which is then followed by the formation
and increase of extracellular space between adjacent cells.
Eventually, cells undergo extensive morphological
changes to finally shape the tubes [4,29]. This defined
sequence of events was impaired in zebrafish embryos
upon deletion of EGFL7 (Figure 3). More specifically,
angioblasts did not segregate and retained tight junctions
across the space where the vascular lumen was supposed
to form. This impairment resulted in the absence of
lumens in the majority of vessels [4]. This particular phe-
notype ascribed an important role to EGFL7 in the pro-
cess of tubulogenesis but the underlying molecular
mechanism remained unclear. The authors showed
EGFL7 promoted adhesion of human umbilical vein
endothelial cells, however, not as efficient as conventional
ECM molecules. In light of the finding that several cell
types favor cell migration over strict adhesion under
intermediate cell adhesion conditions [30], one might
speculate that EGFL7 creates a microenvironment that
facilitates the local motility of endothelial cells during
tube formation. Nevertheless, data involving the effect of
EGFL7 on endothelial cell migration remain controversial
and ambiguous. It has been reported that EGFL7 pro-
moted the migration of several mouse endothelial cell
lines in vitro [13], while other studies showed that EGFL7,
alone or in combination with other ECM proteins, did
not affect the migration of endothelial cells in a modified
Boyden chamber nor random HUVEC motility moni-
tored by live cell microscopy [3,4,20]. A recent study by
Schmidt et al. postulated EGFL7 stimulates collective
migration of endothelial cells within an angiogenic sprout
by maintaining the correct spatial distribution of the
cohort [20]. In addition to the investigation of the role of
EGFL7 in endothelial cell motility and migration, it might
be interesting to study the arrangement of tight junctions
in EGFL7-/- zebrafish embryos because it has been shown
that cell-matrix interactions control the distribution of
cell-cell adhesion molecules and polarity proteins during
lumen formation [31]. Indeed, data recently published by
Durrans et al. demonstrated that the deletion of EGFL7 in
an embryoid body model resulted in the formation of
abnormal endothelial cell aggregations designated as
CD31+ sheets, which lacked a full basement membrane
and cell junctions [32].
EGFL7 in angiogenesis
In contrast to vasculogenesis, the process of angiogenesis
involves the formation of new blood vessels from the pre-
existing vascular network [33]. In most experiments,
angiogenic sprouting is studied although angiogenesis
also proceeds through intussusceptions [34,35]. Angio-
genic sprouting involves a number of tightly regulated
steps: vasodilatation and endothelial permeability,
endothelial cell proliferation and migration, lumen for-
mation as well as endothelial cell survival and vessel
maintenance [36]. Due to the role of EGFL7 in tubulogen-
esis [4] it is reasonable to assume a comparable role for
EGFL7 in angiogenic sprouting. In order to investigate
this matter, Schmidt et al. created two independent
mouse lines harboring EGFL7 deletions [20]. The first
line was generated by application of a retroviral gene trap
vector which was inserted in intron 2, upstream of the
translation initiation codon in exon 3, whereas the second
mouse line was created by homologous recombination
resulting in the removal of the DNA region lasting from
exon 5 to exon 7. 50% of the corresponding EGFL7-/-
embryos died in utero and the surviving mice displayed
severe vascular developmental defects in most tissues
analyzed. More specifically, a delay in blood vessel expan-
sion within coronary, retinal and cranial vascular beds
was observed in the absence of EGFL7. Surprisingly, this
phenotype resolved in later developmental stages and a
functional vasculature formed in all of the examined
organs. This interesting observation may be explained by
the upregulation of EGFL8, also known as VE-statin-2 or
NG3, which is an EGFL7 homolog. Both proteins share
the same overall domain structure and a similar expres-
sion pattern with an overall protein sequence homology
of 35%. The highest levels of EGFL8 are detected in kid-
ney, brain, thymus and lung [5]. The fact that egfl8  is
present in mouse but not in zebrafish could potentially
account for the striking and persistent phenotype
observed in zebrafish embryos upon EGFL7 depletion
that has not been detected in EGFL7-/- mice [4].
In order to unravel the cellular basis for the observed
defects in murine vessel growth, Schmidt et al. performed
a detailed analysis of angiogenic sprout morphology [20].
Namely, they studied angiogenic sprouting, which pro-
ceeds through the coordinated actions of two cell types:
tip cells and stalk cells. Tip cells sense a VEGF gradient in
the surrounding environment and extend filopodia,Nikolic et al. Journal of Angiogenesis Research 2010, 2:9
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which leads the angiogenic sprout in a specific direction.
The trailing stalk cells on the other hand proliferate and
support sprout elongation [37]. Eventually, endothelial
cells reacquire a quiescent phenotype, recently referred to
as phalanx cells, which mediate the stabilization of newly
formed vessel [38].
In wild type animals tip and stalk cells organize within a
single cell layer, while in EGFL7 knock-out mice both cell
types form multiple cell layers similar to the cell aggre-
gates observed in EGFL7 knock-down zebrafish embryos
[4]. Immunohistochemical staining of collagen IV
revealed that this ECM molecule, which is typically local-
ized in the basal membrane, was found within these
enlarged sprouts and was detected between the adjacent
endothelial cells. This suggests that endothelial cells lack-
ing EGFL7 failed to properly detect the sprout boundar-
Figure 3 Role of EGFL7 in lumen formation. (a) During primitive plexus formation angioblasts assemble into vascular cords which are subsequently 
transformed into vascular tubes. Cord-to-tube transition is characterized by cell polarization, redistribution of junctional proteins and eventually, 
changes in cell shape. EGFL7 is secreted by endothelial cells into the extracellular matrix, where it affects the process of lumen formation. (b) In the 
absence of EGFL7 angioblasts fail to separate, which leads to the formation of vessels lacking a vascular lumen.Nikolic et al. Journal of Angiogenesis Research 2010, 2:9
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ies. Previously, it has been shown that EGFL7 supports
the weak adhesion of endothelial cells [4], suggesting
EGFL7 creates an environment where cells easily attach
and detach until properly positioned. In the absence of
EGFL7, however, cells may clump together and build
oversized sprouts resulting in an impaired migration and
delayed vascularization as observed in EGFL7-/- mice.
A recent study of Schmidt et al. provided another com-
pelling clue for resolving the function of EGFL7 protein
in angiogenesis [15]. Most interestingly, a link between
EGFL7 and Notch signaling has been unraveled. The
Notch pathway is evolutionarily conserved and governs
fundamental processes such as development, cell-fate
determination and differentiation [39]. Notch-mediated
signal transduction is based on several key molecules:
four Notch receptor isoforms (Notch1-4) and five canon-
ical ligands of the Delta (Dll1, 3 and 4) or the Jagged type
(Jagged1 and 2) [40]. The role of Dll3 has been controver-
sially discussed and it is not considered a bona fide Notch
ligand [41]. Signaling in this pathway proceeds through
ligand-receptor binding which leads to intra-membrane
proteolysis of the Notch receptor and release of the
Notch intracellular domain (NICD). The activated C ter-
minus of the Notch receptor translocates into the
nucleus, where it associates with the DNA-binding pro-
tein CSL to promote transcription [42]. Interestingly,
Figure 4 EGFL7 and Notch signaling. Notch receptors are expressed on the cellular surface as heterodimers connected by non-covalent interac-
tions. (a) Upon binding of Jagged-type ligands expressed on neighboring cells in trans, Notch receptors undergo a series of proteolytic cleavage 
events releasing the NICDs of the receptors and allowing their translocation into the nucleus. (b) If EGFL7 is present in the surrounding of the cells, it 
competes with Jagged for Notch binding thereby attenuating Notch signaling.Nikolic et al. Journal of Angiogenesis Research 2010, 2:9
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Schmidt et al. demonstrated the binding of EGFL7 to all
four Notch receptors and suggested that EGFL7 acts as a
modulator of Notch receptor activation by its canonical
ligands Jagged1 and Jagged2 [43]. This might have impor-
tant implications in the vascular system since the Notch
pathway plays an indispensable role in the tip-stalk cell
decision during angiogenic sprouting [44-47]. Namely,
high levels of Dll4 expressed on filopodia-rich tip cells
that lead the angiogenic sprout (see EGFL7 in angiogene-
sis) activate Notch receptors present on the adjacent stalk
cells. Although it is not completely understood how this
suppresses the tip cell phenotype, it is believed that the
activation of the Notch pathway causes a downregulation
of the expression of VEGF receptors and consequently
dampens the response of stalk cells to the surrounding
VEGF [45,47]. Recently, Jagged1 has been suggested to be
exclusively expressed on stalk cells where it antagonized
Dll4-mediated activation of Notch receptors. In turn, ele-
vated levels of Jagged1 led to increased angiogenesis and
tip cell numbers [48]. Likely, members of the family of
Fringe glycosyltransferases mediated the differential acti-
vation of Notch receptors by the enhancement of Notch
activation in response to Delta-like ligands, which was
paralleled by a reduction of Notch activity in response to
Jagged-type ligands [49]. Interestingly, a similar pattern of
differential Notch pathway modulation was reported by
Schmidt et al. They demonstrated that EGFL7 acted as an
inhibitor of Notch receptor activation by competition
with Jagged-type ligands (Figure 4) and presented prelim-
inary data suggesting a selective binding of EGFL7 to
Dll4. These findings offered the possibility that EGFL7
affects vascular Notch signaling during angiogenic
sprouting.
miR-126 in angiogenesis
Recently, findings on the role of EGFL7 in angiogenesis
have been supplemented by several papers describing a
role of miR-126 in the vascular system [6,50,51]. Collec-
tively, miRNAs represent a class of about 22 nucleotide
long, non-coding RNAs that have been recognized in
recent years as important regulators of gene expression
[52]. Predominantly, miRNAs repress protein expression
by the inhibition of protein translation and to a lesser
extent by mRNA degradation [53]. Mounting evidence
indicates the importance of miRNAs in blood vessel for-
mation by the regulation of endothelial and smooth mus-
cle cell functions [54,55]. Most interestingly, miR-126 is
located in intron 7 of egfl7 (Figure 2). Currently, it is the
only miRNA known to be specifically expressed in the
endothelial cell lineage and hematopoietic progenitor
cells [6,50,56,57]. A significant role of miR-126 for tumor
development has been suggested by various studies
describing a downregulation of miR-126/miR-126* in pri-
mary tumors and cancer cell lines [10,58-60]. The resto-
ration of miRNA-activity by overexpression of miR-126/
miR-126* led to a reduction of overall tumor growth,
migration and invasiveness [10,58,59], in part by inhibi-
tion of cancer cell proliferation.
Two papers were published back-to-back studying the
function of miR-126 in vessel development by loss of
function experiments either in zebrafish [6] or mouse
[50]. In both cases loss of miR-126 caused similar pheno-
types in vivo: impaired endothelial cell migration during
vessel growth as well as collapsed vessel lumens and a
compromised endothelial tube organization. Analyses on
the molecular level revealed that miR-126 repressed
SPRED1 and PIK3R2, which negatively regulate VEGF
signaling via the MAP kinase and PI3 kinase pathways.
Previous EGFL7 deletion strategies affected the region
encoding miR-126 and most likely, affected the transcrip-
tion of miR-126 as well. Although miR-126 levels have
not been measured in the initial EGFL7 knock-out study,
concerns were raised on the data describing the effects of
EGFL7 on angiogenic sprouting [20]. Indeed, vascular
defects seen in the miR-126-/- model were very reminis-
cent of the original EGFL7 knock-out analyses. To further
address this problematic issue, Kuhnert et al. generated
two mouse lines, one with an EGFL7 protein deletion and
one with a miR-126 deletion that did not show any cross-
perturbation of EGFL7 and miR-126 [51]. The miR-126-/-
mice were born at a frequency of 50% embryonic lethality
and displayed a range of vascular defects similar to the
ones described by Schmidt et al. in EGFL7-/- mice [20]:
hemorrhage, delayed postnatal retinal and cranial angio-
genesis and the presence of abnormally thickened
endothelial sprouts. Surprisingly, Kuhnert's EGFL7-/-
mice were phenotypically normal and born at the
expected frequency. Further, these mice did not display
any of the vascular defects seen in the previously pub-
lished miR-126-/- mice. Taken together, this strongly sup-
ports the possibility that the phenotype of EGFL7-/- mice
described by Schmidt et al. actually reflected the loss of
function of miR-126. Yet another EGFL7 loss-of-function
study putatively affecting miR-126 expression was pre-
sented by Parker et al. who described EGFL7 as an impor-
tant factor for vascular tube formation during zebrafish
development [4]. Indeed, the EGFL7 knock-down pheno-
type observed in zebrafish embryos in this study appears
to resemble the one detected upon miR-126 knock-down
[6]: hemorrhage as well as the presence of vessels with
compromised lumens. However, both phenotypes display
distinct differences, e.g. the block in initial lumen forma-
tion due to the failure of angioblast separation in EGFL7
knock-down embryos. In miR-126 knock-down embryos
lumens are formed but collapse at later stages of zebrafish
development. Most unfortunately, endogenous levels of
miR-126 have not been assessed in the EGFL7 knock-
down study but a downregulation of miR-126 seems lessNikolic et al. Journal of Angiogenesis Research 2010, 2:9
http://www.jangiogenesis.com/content/2/1/9
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likely in this setting. First, two morpholinos have been
used to knock-down EGFL7 in zebrafish which prevented
either EGFL7 mRNA translation or caused the premature
termination of translation. In both cases miR-126 could
still be transcribed as a primary transcript containing the
miR-126 is produced. Second and even more importantly,
P a r k e r  e t  a l .  w e r e  a b l e  t o  r e s c u e  t h e  p h e n o t y p e  t h e y
observed by the co-injection of EGFL7 mRNA together
with a morpholino targeting EGFL7. This suggests that
the tubulogenesis defect they observed was indeed
c a u s e d  b y  t h e  l o s s  o f  E G F L 7  p r o t e i n .  S t i l l ,  a  p o t e n t i a l
interference of this knock-down strategy with the process
of pre-miRNA formation and subsequent miR-126 matu-
ration cannot be fully excluded at this stage.
Interestingly, a recent work demonstrated that EGFL7
is a direct target of the miR-126 in lung cancer cells and
hinted that this could be at least a part of an explanation
for the observed effect of miR-126 on tumourogenesis
[8]. Likewise, Fish et al. described a transcriptional regu-
lation of EGFL7 in human endothelial cells by miR-126
[6]. Taken together, above findings unambiguously dem-
onstrate that miR-126 and EGFL7 share not only a struc-
tural but also a tight functional connection in different
cellular contexts.
Concluding remarks and future perspectives
Current data emphasizes a highly significant role of egfl7
for the development and homeostasis of the vascular sys-
tem. The EGFL7 protein was shown to be an important
factor governing lumen formation during vasculogenesis,
whereas miR-126 harbored within the egfl7 gene played a
crucial role in the process of angiogenesis and mainte-
nance of vessel integrity. This way both molecules might
very well collaborate to shape blood vessels.
Nevertheless, at the current stage there are many unre-
solved issues such as an imminent lack of a defined role of
the EGFL7 protein in angiogenesis or an explanation of
the mechanisms underlying EGFL7's effects on endothe-
lial cells. Further, the functional relationship between the
EGFL7 protein and miR-126 is not clear and one wonders
if both act in synergy or antagonism. The undisputed role
for EGFL7 in blood vessel formation beyond the function
of miR-126 has yet to be proven and the underlying
mechanism unraveled. Mice harboring a specific EGFL7
protein deletion without the confounding effect of the
loss of miR-126 [51] do not show any abnormalities dur-
ing angiogenic sprouting. This could potentially be
explained by the upregulation of the EGFL7 homolog
EGFL8 as indicated above. In this case it might prove use-
ful to study EGFL7/EGFL8 double knock-out mice in
order to understand the effects of the individual proteins
on blood vessel formation. In addition, transgenic mice
expressing EGFL7 under inducible conditions will help to
shed light on the role of EGFL7 in angiogenesis.
Yet another interesting question to be addressed is the
identification of novel EGFL7-interacting molecules on
the surface of vascular cells. Given the fact that EGFL7
incorporates into the ECM, it seems possible that integ-
rins mediate EGFL7's effects on endothelial cells, because
integrins represent a class of receptors responsible for the
interaction of virtually all types of adherent cells with the
ECM. Integrins are indispensible for essential processes
in the vascular system such as proliferation, migration or
survival [61], plus, there is considerable data that suggest
integrins to play a key role in the stimulation of tubular
morphogenesis and the activation of endothelial cells
[62,63]. This makes them prime candidates to be studied
as mediators of EGFL7's effects on endothelial cells.
Further, it seems worthwhile to study the role of EGFL7
in cancer formation and progression as the role of egfl7 in
angiogenesis points towards an interesting role of EGFL7
in tumor development. There have been several reports
of EGFL7 expression in various tumors and tumor cell
lines [4,5,64]. A recent study proposed EGFL7 increases
the metastatic potential of human hepatocellular carci-
noma by driving migration and invasion of tumor cells
[64]. Taking into account the previously discussed data
on the involvement of miR-126 in cancer it would be of
interest to address the potential interplay of the EGFL7
protein and miR-126 within the tumor vasculature as well
as the tumor cells themselves. Additionally, considering
the dual effects of EGFL7 on endothelium and the tumor
parenchyma, the development of novel agents targeting
EGFL7 and its homolog EGFL8 may prove to be valuable
additions to the already existing array of therapeutic
strategies against cancer.
In sum, egfl7 is a novel promising gene in vessel devel-
opment. Current data emphasizes a role in vasculogene-
sis and angiogenesis by the modulation of endothelial and
smooth muscle cells (Figure 5). Molecularly, these effects
might be mediated by various signaling pathways. How-
ever, further work needs to address which of these possi-
bilities apply and whether or not they all act in concert.
As a modulator of vessel formation the egfl7 gene might
prove useful for the treatment of vascular development
disorders, cardiovascular diseases or cancer by tackling
tumor neovascularization. Accordingly, the future is
bright for the EGFL7/miR-126 alliance of angiogenesis.
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